Penumbra Inc (PEN) News & EventsPENNews & EventsPenumbra Inc

Incuvate Sues Penumbra for Patent Infringement

Incuvate announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. "The lawsuit, filed August 19, 2026, alleges that Penumbra's recently launched THUNDERBOLT(TM) Neurovascular Thrombectomy System and related components infringe five Incuvate patents directed to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures... Through this lawsuit, Incuvate seeks to hold Penumbra accountable for what Incuvate alleges is Penumbra's unauthorized and willful infringement of the technologies embodied in the asserted patents. Incuvate is seeking damages, injunctive relief, and other remedies described in the complaint," the company stated.

Boston Scientific Acquires Penumbra, No 2026 Financial Guidance Provided

Reports Q2 revenue $390M, consensus $390.08M. Given the pending acquisition of Penumbra by Boston Scientific (BSX), the company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026.

Penumbra THUNDER Study Shows Effectiveness of THUNDERBOLT

Penumbra announced the results of THUNDER, an Investigational Device Exemption study, to evaluate the safety and effectiveness of THUNDERBOLT, the company's novel computer assisted vacuum thrombectomy system, in stroke patients with emergent large vessel occlusion. The data were presented this week during a late-breaking session at the Society of NeuroInterventional Surgery 23rd Annual Meeting. "Mechanical thrombectomy is considered frontline treatment for stroke; however, current technologies may not fatigue and completely ingest the clot quickly or effectively at the site of the occlusion," said Donald Frei, M.D., co-principal investigator of THUNDER and neurointerventional radiologist at Swedish Medical Center, Denver, CO. "The THUNDER study demonstrated a high rate of complete clot ingestion with THUNDERBOLT, along with a low rate of complications-an important combination when striving for optimal patient outcomes." THUNDER met its predefined performance goal, with 87.5% of cases achieving successful reperfusion, defined as mTICI 2b-3, after treatment with THUNDERBOLT. Notably, post-THUNDERBOLT, mTICI 2c-3 was achieved 70.4% of the time, which is associated with significantly better functional recovery and lower complication rates.